Hikma Pharmaceuticals (HIK) — Dividend Yield: 5.21%

Sector: Pharmaceuticals and Biotechnology | Market Cap: £2,640.09 | EPIC: HIK

Hikma Pharmaceuticals (LON: HIK) is an international pharmaceutical company listed on the FTSE 100, with a market capitalisation of approximately £2.6 billion. The company develops, manufactures, and markets a broad range of generic and branded pharmaceutical products across three divisions: Injectables, the largest and most profitable segment; Generics, focused on the US oral solid-dose market; and Branded, serving the Middle East and North Africa region. Hikma operates manufacturing facilities in the US, Europe, and the MENA region.

Hikma's dividend yield of approximately 5.21% provides one of the highest yields among healthcare stocks in the FTSE 100. The company has a progressive dividend policy, increasing payments annually in line with earnings growth. Hikma's diversified business model, spanning geographies and pharmaceutical formats, provides the revenue stability needed to support consistent shareholder distributions.

For investors seeking pharmaceutical exposure within the FTSE 100, Hikma offers a differentiated generic and specialty drug manufacturer with unique geographic advantages. The company's injectable pharmaceuticals business is particularly valuable, as injectable generics face higher barriers to entry than oral dosage forms, resulting in less competition, stronger pricing, and higher margins. Hikma's FDA-approved manufacturing facilities in the US give it credibility and market access in the world's largest pharmaceutical market.

Hikma's branded business in the Middle East and North Africa benefits from the region's growing healthcare spending, expanding insurance coverage, and increasing demand for quality medicines. The company's deep understanding of MENA markets, established distribution networks, and strong physician relationships create sustainable competitive advantages. Hikma's pipeline of new injectable and generic products provides revenue growth visibility. For FTSE 100 investors seeking high-yield healthcare exposure with unique emerging market positioning and injectable pharmaceutical expertise, Hikma Pharmaceuticals is a compelling and distinctive option.